# First-line Palbociclib and Endocrine Therapy for Patients With HR+/HER2- Advanced Breast Cancer in the Real-world Setting.

> **NCT04767594** · — · ACTIVE_NOT_RECRUITING · sponsor: **Pfizer** · enrollment: 1407 (actual)

## Conditions studied

- Breast Neoplasms

## Interventions

- **DRUG:** Palbociclib + endocrine therapy

## Key facts

- **NCT ID:** NCT04767594
- **Lead sponsor:** Pfizer
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2020-10-27
- **Primary completion:** 2028-04-03
- **Final completion:** 2028-04-30
- **Target enrollment:** 1407 (ACTUAL)
- **Last updated:** 2026-04-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04767594

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04767594, "First-line Palbociclib and Endocrine Therapy for Patients With HR+/HER2- Advanced Breast Cancer in the Real-world Setting.". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT04767594. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*